LIF and multiple sclerosis: Further, by day 24, 80% of placebo animals had died, compared with 45% of LIF-treated (Rx) animals.11 Similarly, promising results have been reported using a different model of multiple sclerosis as well as in a mouse model of spinal cord injury.12,13 Importantly, in a clinical trial, recombinant human LIF, under the trade name of Emfilermin, was tested in a randomized, double-blinded, placebo-controlled phase II trial for chemotherapy-induced peripheral neuropathy.